Parexel International
United States
About Parexel International
521 articles about Parexel International
-
Mark A. Goldberg, MD Joins Intensity Therapeutics, Inc. Board of Directors
5/17/2018
Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary cancer immune-based drug products for direct intratumoral injection, today announced that Mark A. Goldberg, MD has been appointed to the Company's Board of Directors effective May 1, 2018.
-
University of Texas System Initiative, Clinical Trials Xpress (CTX), Named as a PAREXEL Strategic Site Alliance Network Member
4/26/2018
Clinical Trials Xpress has been named by PAREXEL, the world's leading innovator of biopharmaceutical services, as a member of its Global Site Alliance Network.
-
PAREXEL Announces Appointment of Peyton Howell as Chief Commercial and Strategy Officer
4/25/2018
Proven Healthcare Industry Leader will head PAREXEL’s Commercial Strategy
-
PAREXEL’s Randomization and Trial Supply Management Service Recognized as Leader in Second Consecutive Industry Standard Research Benchmark Report
4/17/2018
PAREXEL’s ClinPhone® Randomization and Trial Supply Management cited as the most preferred and widely used Interactive Response Technology solution
-
PAREXEL and Meiji Pharmaceutical University Announce Academic Program to Develop Japan’s Biopharmaceutical Workforce
4/9/2018
Joint Program for Clinical Research and Clinical Trial Management to be offered through the PAREXEL Academy
-
PAREXEL Introduces Integrated Medical Writing Solutions Service Offering
3/21/2018
Comprehensive end-to-end services enable effective, streamlined communication with key stakeholders across all stages of drug development and commercialization
-
PAREXEL and CHA Medical Group Partner to Enhance Early Phase Clinical Research in Korea
3/13/2018
Collaboration combines best-in-class offerings from CHA and PAREXEL to enhance early phase clinical trials in growing hub for drug development
-
After 35 years at the helm of Parexel International Corporation, co-founder Josef von Rickenbach is stepping down from his role as chief executive officer.
-
PAREXEL Appoints Jamie Macdonald as Chief Executive Officer
3/5/2018
PAREXEL International Corporatio announced the appointment of Jamie Macdonald as Chief Executive Officer (CEO) effective March 15, 2018.
-
PAREXEL Receives Two Industry Recognitions for its Diverse and Flexible Workplace
2/26/2018
PAREXEL International Corporation, the world’s leading innovator of biopharmaceutical services, today announced that the Company has been recognized for its diverse and flexible workplace by Forbes and FlexJobs.
-
PAREXEL Introduces Biological Sample Lifecycle Management Service to Address Growing Demand Across Drug Development
2/12/2018
PAREXEL today launched its Biological Sample Lifecycle Management service, enabling optimal use of human biological samples.
-
PAREXEL Announces Enhanced Global Data Operations Offering to Drive Efficiencies for Life Science Companies
12/18/2017
PAREXEL today introduced its enhanced GDO solution, with augmented processes and expertise that further bolsters its world leading clinical data services, including data management, statistical programming and biostatistics.
-
PAREXEL Launches Perceptive Cloud for the Life Sciences Industry
12/12/2017
PAREXEL introduced the Perceptive Cloud to the life sciences industry, as part of the organization’s recent alliance with Microsoft Corp.
-
PAREXEL Expands Global Regulatory Services With Addition of Senior Executives From FDA and Oncology Industry
11/15/2017
The new appointments enhance PAREXEL’s leadership and expertise in bringing commercially viable, reimbursable products to market.
-
PAREXEL Enhances Its Active Tracking Service with Bluetooth Capability to Improve Monitoring of Temperature-Controlled Medication
10/26/2017
PAREXEL today announced a new feature for its ClinPhone RTSM Mobile App that addresses the workflow and safety issues commonly associated with the packaging, transport, and storage of temperature-sensitive medications.
-
Microsoft And PAREXEL Form Cloud Technology Alliance Aimed at Accelerating the Pace of Drug Development
10/24/2017
Microsoft Corp. and PAREXEL International Corp., a leading global biopharmaceutical services organization, on Tuesday announced a technology development alliance aimed at driving innovation across the life sciences industry with technology powered by Microsoft Azure.
-
Pamplona Capital Management Completes Acquisition Of PAREXEL
10/2/2017
-
PAREXEL Receives Shareholder Approval For Proposed Acquisition By Pamplona Capital Management
9/18/2017
-
PAREXEL Launches Real-World Data Service Offering To Drive Value Demonstration Of New Treatments
9/6/2017
-
PAREXEL Reports Fourth Quarter And Fiscal Year 2017 Results
8/29/2017